Targeted Exon Skipping of NF1 Exon 17 as a Therapeutic for Neurofibromatosis Type I

Initial in silico analysis predicted exons that can be skipped with minimal loss of neurofibromin function, which was confirmed with in vitro assessments utilizing an neurofibromatosis type 1 (Nf1) cDNA-based functional screening system.